Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Leuprolide | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Leuprolide. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Goserelin. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Azithromycin. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Moxifloxacin. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Ranolazine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Sulfisoxazole. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Amitriptyline. |
| Methadone | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Methadone. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Diltiazem. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Clozapine. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Sulpiride. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Nimodipine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Promazine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Prochlorperazine. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Droperidol. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Imipramine. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Chlorpromazine. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Farnesyl thiopyrophosphate. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Ciprofloxacin. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Fluorouracil. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Perflutren. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Cinnarizine. |
| Atropine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Atropine. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Chloroquine. |
| Efavirenz | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Efavirenz. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Adenosine. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Pentamidine. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Gadobenic acid. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Carbinoxamine. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Dolasetron. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Roxithromycin. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Nalidixic acid. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Cinoxacin. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Loperamide. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Granisetron. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Ondansetron. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Levosimendan. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Mesoridazine. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Desloratadine. |
| Telithromycin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Telithromycin. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Lomefloxacin. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Dimenhydrinate. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Primaquine. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Papaverine. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Chlorpheniramine. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Nifedipine. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Levofloxacin. |
| Gemifloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Gemifloxacin. |
| Ofloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Ofloxacin. |
| Propafenone | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Propafenone. |
| Flecainide | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Flecainide. |
| Clarithromycin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Clarithromycin. |
| Levacetylmethadol | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Levacetylmethadol. |
| Saquinavir | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Saquinavir. |
| Clomipramine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Clomipramine. |
| Mibefradil | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Mibefradil. |
| Probucol | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Probucol. |
| Aceprometazine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Aceprometazine. |
| Terlipressin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Terlipressin. |
| Prenylamine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Prenylamine. |
| Fluspirilene | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Fluspirilene. |
| Lofexidine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Lofexidine. |
| Azimilide | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Azimilide. |
| Pracinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Pracinostat. |
| Technetium Tc-99m ciprofloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Technetium Tc-99m ciprofloxacin. |
| Garenoxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Garenoxacin. |
| Tedisamil | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Tedisamil. |
| Tucidinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Tucidinostat. |
| Telavancin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Telavancin. |
| Pazopanib | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Pazopanib. |
| Nemonoxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Nemonoxacin. |
| Panobinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Panobinostat. |
| Nilvadipine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Nilvadipine. |
| Antazoline | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Antazoline. |
| Crizotinib | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Crizotinib. |
| Bedaquiline | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Bedaquiline. |
| Fendiline | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Fendiline. |
| Eperisone | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Eperisone. |
| Butriptyline | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Butriptyline. |
| Ceritinib | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Ceritinib. |
| Lenvatinib | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Lenvatinib. |
| Melperone | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Melperone. |
| Benidipine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Benidipine. |
| Dexchlorpheniramine maleate | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Dexchlorpheniramine maleate. |
| Amifampridine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Amifampridine. |
| Mocetinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Mocetinostat. |
| Entinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Entinostat. |
| Gilteritinib | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Gilteritinib. |
| CUDC-101 | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with CUDC-101. |
| Simendan | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Simendan. |
| Ricolinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Ricolinostat. |
| Mizolastine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Mizolastine. |
| Abexinostat | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Abexinostat. |
| Oxatomide | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Oxatomide. |
| Sitafloxacin | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Sitafloxacin. |
| Sultopride | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Sultopride. |
| Otilonium | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Otilonium. |
| Nizofenone | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Nizofenone. |
| Bunaftine | The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Bunaftine. |